Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02061813 · ClinicalTrials.gov registry record · Phase 1
Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion
A Phase 1 study, sponsored by Dr. Reddy's Laboratories Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02061813: Completed Phase 1 study, sponsored by Dr. Reddy's Laboratories Limited.
NCT02061813 is a Phase 1 study that has completed, run by Dr. Reddy's Laboratories Limited. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02061813, a Phase 1 study, has completed, sponsored by Dr. Reddy's Laboratories Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the irritation potential of repeat applications of abametapir lotion on normal skin.
Primary Outcome
The evaluation of irritation is based on Modified Berger procedure and is accepted as standard methodology for assessment of cumulative irritation potential. The assessment of all patch sites for irritation symptoms will be visually assessed by a trained evaluator using the numerical equivalents (0-7) where 0 is the least irritation potential and 7 is the maximum irritation potential. The scoring will be done on daily basis from baseline through Day 21 visit. The final reported outcome is a mean
Interventions
- DRUG Placebo
- DRUG Saline 0.9%
- DRUG Abametapir Lotion 0.74% w/w
- DRUG Sodium Lauryl Sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
What the finished NCT02061813 record still lists
NCT02061813 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02061813 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02061813 about?
NCT02061813 is a clinical study titled "Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion". The purpose of the study is to determine the irritation potential of repeat applications of abametapir lotion on normal skin.
What is the current status of trial NCT02061813?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2014-01. Estimated completion is 2014-05.
What interventions are being tested in trial NCT02061813?
The interventions under investigation include: Placebo (DRUG), Saline 0.9% (DRUG), Abametapir Lotion 0.74% w/w (DRUG), Sodium Lauryl Sulfate (DRUG).
Who is sponsoring clinical trial NCT02061813?
This trial is sponsored by Dr. Reddy's Laboratories Limited, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02061813's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia